{"id":454035,"date":"2025-12-17T20:49:10","date_gmt":"2025-12-17T20:49:10","guid":{"rendered":"https:\/\/www.europesays.com\/us\/454035\/"},"modified":"2025-12-17T20:49:10","modified_gmt":"2025-12-17T20:49:10","slug":"breckenridge-duloxetine-refund-program","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/454035\/","title":{"rendered":"Breckenridge duloxetine refund program"},"content":{"rendered":"<p>Breckenridge Pharmaceutical Inc. has reached a class action settlement resolving claims that its generic duloxetine (Cymbalta) contained a cancer-causing impurity. <\/p>\n<p>In 2024, Breckenridge <a href=\"https:\/\/www.pharmacy.ca.gov\/about\/recall_alerts\/050124_breckenridge.pdf\" style=\"text-decoration: underline;font-weight: bold\" target=\"_blank\" rel=\"noopener\">recalled generic duloxetine<\/a> products. Duloxetine is an antidepressant that is also used to treat anxiety, diabetic nerve pain, fibromyalgia and chronic pain.<\/p>\n<p>While Breckenridge denies any wrongdoing, it agreed to both a class action settlement and a duloxetine recall refund program to resolve these allegations.<\/p>\n<p>Under the generic Cymbalta settlement, eligible consumers may have two separate ways to receive a refund:<\/p>\n<ul>\n<li>a Class Action Settlement covering certain past purchases, and<\/li>\n<li>a Future Refund Program for products subject to a recall initiated after May 22, 2025.<\/li>\n<\/ul>\n<p>Class Action Settlement Refund Program<\/p>\n<p>Under the terms of the class action settlement, eligible consumers who paid for a prescription of Breckenridge duloxetine before May 22, 2025, may be entitled to a cash payment, depending on the product purchased and the documentation provided. <\/p>\n<ul>\n<li>Class members can receive a single $5 payment with proof of purchase, such as pharmacy or insurance records.<\/li>\n<li>Class members who purchased duloxetine from recalled lot numbers may receive a single $7.50 payment with proof of purchase or documentation showing the affected lot number.<\/li>\n<li>Instead of these flat payments, some consumers may qualify for up to $10 per prescription if they were unable to use their medication due to the recall. To qualify, claimants must provide proof of purchase and either return unused recalled medication or submit a sworn certification.<\/li>\n<\/ul>\n<p>By participating in the class action settlement, class members release certain economic claims related to duloxetine purchases made during the settlement period.<\/p>\n<p>Claims under the Class Action Settlement Refund must be submitted by Dec. 27, 2025.<\/p>\n<p>2. Future Refund Program<\/p>\n<p>In addition to the class action settlement, Breckenridge has established a separate Future Refund Program.<\/p>\n<p>The Future Refund Program applies only to Breckenridge duloxetine recalled after May 22, 2025.<\/p>\n<p>Under this program, eligible consumers may receive a refund of their actual out-of-pocket costs for unused recalled duloxetine, provided they return the medication and submit a valid claim.<\/p>\n<p>Consumers may be eligible for a Future Refund Program refund even if they also submitted a claim under the class action settlement, as long as the recall occurred after May 22, 2025.<\/p>\n<p>Claims under the Future Refund Program must be submitted by Jan. 1, 2028.<\/p>\n","protected":false},"excerpt":{"rendered":"Breckenridge Pharmaceutical Inc. has reached a class action settlement resolving claims that its generic duloxetine (Cymbalta) contained a&hellip;\n","protected":false},"author":3,"featured_media":454036,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[208212,210,1060,67,132,68],"class_list":{"0":"post-454035","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-featured-settlement","9":"tag-health","10":"tag-medication","11":"tag-united-states","12":"tag-unitedstates","13":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115736881922954518","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/454035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=454035"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/454035\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/454036"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=454035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=454035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=454035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}